ASH 2024: CAR-T
The phase 1b study of CAR22 is ongoing, and investigators are currently looking to enroll more patients.
Dr. Matthew Cortese reported that CAR T-cell therapy appears to overcome some of the adverse prognostic impact.
The study used a standard 3+3 dose escalation design to evaluate the results of SYNCAR-001 plus STK-009.
Data support rituximab over watchful waiting in front-line therapy for low-tumor-burden follicular lymphoma, study concludes.
According to Jeremey S. Abramson, MD, TRANSCEND FL showed the highest CR ever reported in high-risk follicular lymphoma.
Results from the phase 1 ENABLE-1 study show complete responses comparable to commercial CAR Ts in B-cell NHL.
CTX112, a next-generation allogeneic CRISPR-Cas9–engineered showing encouraging results in B-cell malignancies.
The approach demonstrated safety and produced response in B-ALL, DLBCL, follicular lymphoma, and MCL.
Encouraging initial study findings in mice will inform the design of a BHB supplementation trial in human patients.
Results from the TRANSCEND CLL 004 show continued benefit of lisocabtagene maraleucel for R/R CLL treatment.
A large, multicenter retrospective study found favorable efficacy and toxicity with this approach.
Odronextamab monotherapy showed promising efficacy in patients with high-risk, grade 1-3a follicular lymphoma.
Robust responses with favorable safety has been demonstrated with tisagenlecleucel in relapsed or refractory Fl.
Favorable preclinical outcomes were demonstrated with VX765 treatment.
Phase 1 study results hint response durability for novel CAR-T agent, CAR22 in certain patients with large B-cell lymphoma.
Molecular features typically associated with inferior outcomes did not significantly affect survival or CAR-T response.
Liso-cel plus ibrutinib demonstrates substantial efficacy, deep remissions, and manageable safety.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.